Amgen has entered into a collaboration with the renowned Brigham and Women’s Hospital in Boston, Mass., that may identify the genetic variations in American women underlying a range of serious illnesses, including heart disease, stroke, diabetes, breast cancer and osteoporosis. The Women’s Genome Health Study will survey genetic differences among 28,000 initially healthy American women who are enrolled in an ongoing study conducted by Brigham and Women’s Hospital and the National Heart, Lung and Blood Institute and have been tracked for more than a decade for the development of many common health disorders.
Amgen’s Joe Miletich, senior vice president, Research and Development, noted the importance of the Women’s Genome Health Study: “The sheer size and richness of these combined databases are unprecedented in medicine. As these women have already been followed for over a decade for various health events, this work may have a significant impact on healthcare research when the data are made available to scientists worldwide who can use them to rapidly advance our understanding of disease in women.”
To read the full press release, click here.